Comparison of Mean Glasgow Outcome Score in Patients with Traumatic Brain Injury after Magnesium Sulphate Therapy and Placebo. A Prospective Study of Shaikh Zayed Hospital Lahore

KAZIM ALI¹, MUHAMMAD IRFAN³, RABIA ABBAS³
MUHAMMAD AFAQ SARWAR¹, KAMRAN HUSSAIN¹

Departments of ¹³Neurosurgery, ²Hematology, Shaikh Zayed Hospital
³Punjab Institute of Neurosciences (PINS), Lahore – Pakistan

DOI 10.36552/pjns.v24i2.451

ABSTRACT

Objective: Traumatic brain injury (TBI) is the number one cause of death under 44 years of age; in spite of this fact, there is no standard available pharmacological agent for the treatment of brain injury. It has a poor prognosis when misdiagnosed or a delayed treatment can lead to significant morbidity. We evaluated the effectiveness of magnesium sulphate treatment for the management and outcome of TBI.

Material and Methods: The prospective cases (n = 112) of TBI were included from Department of Neurosurgery, Shaikh Zayed Hospital, Lahore. Patients were split into two groups. Magnesium sulphate treatment group (n = 56) and placebo group (n = 56). Detailed history of patients was taken along with comprehensive examinations with CT scans. 56 TBI patients were given standard treatment plus magnesium sulphate and remaining 56 patients received just standard treatment.

Results: Mean age of the magnesium supplement therapy group was 36.83 ± 13.45 years while in the placebo group was 33.64 ± 12.88 years). Majority 28 (67.9%) were male in the magnesium sulphate group while 37 (66.1%) were in the placebo group. Mean duration passed between hospital presentation and traumatic brain injury was 4.98 ± 2.32 hours in the magnesium sulphate group while it was 5.05 ± 2.48 in the placebo group. Mean Glasgow outcome score was 3.57 ± 1.33 in the magnesium sulphate group while 2.78 ± 1.23 in the placebo group and this difference was statistically significant.

Conclusion: There is significant improvement in GOS after magnesium sulphate therapy in patients with traumatic brain injury versus placebo group as noted in the results.

Keywords: Glasgow Outcome Score, Traumatic Brain Injury.

INTRODUCTION

An external force when comes in contact to the head or body causes central nervous system dysfunction and damage that results in injury to the brain (TBI); there are several scales available to quantify the TBI. The scales which are routinely used for assessment include the Glasgow Coma Scale (GCS) score and the time period of loss of consciousness or post traumatic amnesia.¹

Severe traumatic brain injury (TBI) is a leading cause of morbidity and mortality worldwide.² TBI leads to amnesia, loss of consciousness, paralysis, and even death; the average age of patients with brain injury ranged from 27 to 59.67 years.³ The overall mild: moderate: severe ratio was 55: 27.7: 17.3 based on Glasgow Coma Scale (GCS). Asia ranked highest in percentage of Motor vehicle related TBIs. The percentage of fall and work related TBIs was highest.³

The number one cause of death under 44 years of age is TBI; in spite of this fact, there is no standard
available pharmacological agent for the treatment of brain injury. Medical management of patients with TBI is part of pre hospital triage. The aim of the treatment is to protect the brain from damage that occurs later (secondary brain insult). In the early phase of TBI, the excitotoxicity leads to necrosis, apoptosis, necroptosis, autophagy, or pyroptosis. Excitotoxic events and their relationship to neuronal death pathways in TBI has been extensively researched. Even then, after 45 years of research most therapies against excitotoxic events have not been effective clinically. There are very few options available to improve clinical outcomes after traumatic brain injury in spite of many years of research.

With reference to various researches, magnesium sulfate administered after a brain injury (diffuse axonal injury) has proved to be a useful protective agent for central nervous system. In a research significant improvement was noticed in Glasgow outcome scale after acute magnesium sulphate therapy in patients with TBI at 3 months. In another study, patients admitted within one hour after severe brain injury who fulfill the inclusion standards were selected with random sampling. They were divided into two groups.

**Dose**

Patients were given a bolus dose of fifty mg/kg magnesium sulfate and then after every six hours, fifty mg/kg of MgSO₄ was given up to twenty four hours after the brain injury.

The outcome was assessed by Glasgow Coma Scale (GCS) score, mortality, and motor function scores which were checked up to two months after TBI. There was statistically significant improvement of GCS score at two months after trauma in patients who were given Magnesium Sulphate. There was also improvement in the Motor function scores of patients who were given MgSO₄. Although, this was not statistically significant (P equal to 0.51). Several studies have shown around 50% fall in brain free magnesium levels within hours after TBI. Clinical outcome is significantly improved when magnesium levels are restored back to baseline with various pharmacological approaches available.

In a study done by Ling Zhao and others, there was higher GCS and significant lower GOS in MST (magnesium sulphate therapy) group as compared to placebo group. GCS scores on 3rd day in the Magnesium sulphate therapy group (7.39 ± 2.07 with MgSO₄ and 6.23 ± 2.29 without MgSO₄). The mean Glasgow outcome score was significantly lower in the MgSO₄ group at discharge and one month post discharge.

A current meta-analysis of existing randomized controlled trials suggested that magnesium sulfate therapy is a useful agent in improving the Glasgow Outcome Scale and Glasgow Coma Scale scores, this is an encouraging data for TBI treatment.

Magnesium has neuro protective role through various mechanisms, including NMDA receptor blockade, vascular smooth muscle relaxation, inhibition of excitatory neurotransmitter release and blockade of calcium channels.

The aim of the study was to determine mean GCS and Glasgow outcome score in patients with traumatic brain injury after magnesium sulphate therapy. We designed this study to test the notion that treating a traumatic brain injury in patients with magnesium would improve outcome in short and long term after trauma. It will be a useful addition to the community knowledge. Data can be used by the care providers in investigating the problem and its management.

**MATERIAL AND METHODS**

**Study Setting**

The study design was quasi experimental. This study was conducted in the Department of Neurosurgery at Sheikh Zayed Hospital, Lahore from May 2018 to July 2019. We enrolled 112 patients who were presented with traumatic brain injury (TBI). They were divided into two groups; 56 patients in Magnesium sulphate group and 56 patients in the placebo group. Informed consents were taken from all patients or their attendants conformed to institutional ethical standards.

**Sampling Technique**

Patients were selected on the basis of non-probability consecutive sampling. Patients background information and clinical presentations were recorded. Patients were evaluated consisting of a detailed history, physical examination (history of LOC, ENT bleed, fits, vomiting, antegrade and retrograde amnesia).

**Inclusion Criteria**

We included patients of both genders with traumatic brain injury with age between 18 – 70 years who gave consent.
Exclusion Criteria
We excluded pregnant women, children less than 18 years of age, patients with poly trauma, patients with significant metabolic diseases (CRF, CCF etc) and those patients who did not give consent.

Clinical Information
All patients had undergone a CT scan (brain plain). The routine lab tests were conducted for CBC, coagulation profile, PT, APTT, renal and liver profiles (LFTs, RFTs) and other relevant tests for the stabilization for surgical intervention. 56 TBI patients were given standard treatment plus magnesium sulphate and remaining 56 patients received just standard treatment.

Treatments of TBI
The regular mode of treatment for TBI was that they received standard protocol treatment(patient is managed according to brain trauma guidelines, N.G/ Foleys passed, intravenous fluids, Mannitol infusion, antibiotics, nutrition, antiepileptic drugs as required, surgery if indicated) and along with this patients were given magnesium sulphate as an add on therapy. Blood samples for serum magnesium levels drawn on two occasions, at the time of admission and on the 3rd day. Treatment guidelines consisted of an initial loading dose of 50 mg/kg magnesium sulfate and then 15 mg/kg T.D.S up to 48 hours after the trauma. The clinical outcome was evaluated by using GOS (at 1 month).

Data Analysis
Data analysis was performed in SPSS (v.22.0, IBM Corporation) software. Categorical variables like gender were described as frequencies and percentages. Quantitative variables like age, weight, height, was described as mean +/- standard deviation. The continuous variable like serum Magnesium levels and age was presented in the form of mean and S.D. Qualitative variable like gender and grades of Glasgow Outcome Scale, was presented in the form of frequency and percentages. Data was stratified by age and gender with regard to outcome variable, i.e., Glasgow outcome score. A t test was used to compare the means of parameters between the groups. A p value ≤ 0.05 was considered as significant.

RESULTS
There were 112 patients with primary brain trauma enrolled in the Neurosurgery Department of Shaikh Zayed Hospital, Lahore. Patients were split into two groups (n = 56) Magnesium sulfate group and (n = 56) placebo group.

Age Incidence
Mean age of the magnesium supplement therapy group was 36.8 years, while in the placebo group was 33.6 years (Table 1).

Table 1: Distribution of the Mean Age in the Study Groups.

<table>
<thead>
<tr>
<th>Group of Treatment</th>
<th>Mean</th>
<th>Std. Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium Supplement therapy</td>
<td>36.83</td>
<td>13.45</td>
</tr>
<tr>
<td>Placebo therapy</td>
<td>33.64</td>
<td>12.88</td>
</tr>
</tbody>
</table>

Gender Distribution
Table 2 shows that the majority were male, 38 (67.9%) in the magnesium sulfate group while 37 (66.1%) were in the placebo group.

Table 2: Distribution of the Gender in the Study groups.

<table>
<thead>
<tr>
<th>Gender of Patients</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>38</td>
</tr>
<tr>
<td>Female</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td>Magnesium Supplement therapy</td>
<td>67.9%</td>
</tr>
<tr>
<td>Placebo therapy</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>66.1%</td>
</tr>
<tr>
<td></td>
<td>33.9%</td>
</tr>
<tr>
<td></td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Table 3: Distribution of the Duration of the traumatic brain injury in the study groups.

<table>
<thead>
<tr>
<th>Group of Treatment</th>
<th>Mean</th>
<th>Std. Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of trauma (in hours)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium Supplement therapy</td>
<td>4.98</td>
<td>2.32</td>
</tr>
<tr>
<td>Placebo therapy</td>
<td>5.05</td>
<td>2.48</td>
</tr>
</tbody>
</table>
Duration Since Injury
Table 3 shows mean duration passed between hospital presentation and traumatic brain injury was 4.98 hours in the magnesium sulfate group while it was 5.05 in the placebo group.

Statistical Analysis
After applying t test it was evaluated that mean Glasgow outcome score was 3.57 ± 1.33 in the magnesium sulfate group while it was 2.78 ± 1.23 in the placebo group and this difference was statistically significant (Table 4).

Stratification of Data
Data was stratified for the impact of the age, gender and duration elapsed between trauma and presentation of patients and presented in tables 5 – 7.

Table 5 describes the stratification of the Glasgow outcome score in the treatment groups with respect to age. Glasgow outcome score in patient with age < 30 years was 3.65 ± 1.20 in magnesium sulfate group vs. 2.65 ± 1.19 in the placebo group. GOS, in patients with age > 30 years was 3.45 ± 1.41 in magnesium sulfate group vs. 2.93 ± 1.28 in the placebo group.

Table 6 shows the stratification of the Glasgow outcome score in the treatment groups with respect to gender. Glasgow outcome score in male patients was 3.48 ± 1.30 in magnesium sulfate group vs. 2.73 ± 1.28 in the placebo group. GOS in female patients was 3.73 ± 1.14 in magnesium sulfate group vs. 2.88 ± 1.40 in the placebo group.

Table 7 shows the stratification of the Glasgow Outcome score in the treatment groups with respect to duration of Disease. Glasgow outcome score in patient after 1 – 6 months post TBI was 3.50±1.23 in magnesium sulfate group vs. 2.60 ± 1.26 in the placebo group. GOS in patients > 6 hours of TBI was 3.75 ± 1.14 in magnesium sulfate group vs. 2.88 ± 1.40 in the placebo group.

CT scans are shown in figures. Figure 1

Table 4: Comparison of Mean Glasgow Outcome Score in the Both Study groups.

<table>
<thead>
<tr>
<th>Glasgow Outcome Score</th>
<th>Group of treatment</th>
<th>Mean</th>
<th>Std. Deviation</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Magnesium Supplement therapy</td>
<td>3.57</td>
<td>1.23</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>Placebo therapy</td>
<td>2.78</td>
<td>1.33</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Stratification of the Glasgow Outcome score in the treatment groups with Respect to Age.

<table>
<thead>
<tr>
<th>Age</th>
<th>Group of Treatment</th>
<th>Glasgow Outcome Score</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 – 30 years</td>
<td>Magnesium Supplement therapy</td>
<td>3.65 ± 1.20</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>Placebo therapy</td>
<td>2.65 ± 1.19</td>
<td></td>
</tr>
<tr>
<td>&gt;30 years</td>
<td>Magnesium Supplement therapy</td>
<td>3.45 ± 1.41</td>
<td>0.16</td>
</tr>
<tr>
<td></td>
<td>Placebo therapy</td>
<td>2.93 ± 1.28</td>
<td></td>
</tr>
</tbody>
</table>

Table 6: Stratification of the Glasgow Outcome score in the treatment groups with Respect to Gender.

<table>
<thead>
<tr>
<th>Gender</th>
<th>Group of Treatment</th>
<th>Glasgow Outcome Score</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>Magnesium Supplement therapy</td>
<td>3.48 ± 1.30</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Placebo therapy</td>
<td>2.73 ± 1.28</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>Magnesium Supplement therapy</td>
<td>3.73 ± 1.14</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>Placebo therapy</td>
<td>2.88 ± 1.40</td>
<td></td>
</tr>
</tbody>
</table>

Table 7: Stratification of the Glasgow Outcome score in the treatment groups with Respect to Duration of Disease.

<table>
<thead>
<tr>
<th>Duration of Disease</th>
<th>Group of Treatment</th>
<th>Glasgow Outcome Score</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 – 6 months</td>
<td>Magnesium Supplement therapy</td>
<td>3.50 ± 1.23</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>Placebo therapy</td>
<td>2.60 ± 1.26</td>
<td></td>
</tr>
<tr>
<td>&gt; 6 hours</td>
<td>Magnesium Supplement therapy</td>
<td>3.75 ± 1.17</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>Placebo therapy</td>
<td>3.22 ± 1.48</td>
<td></td>
</tr>
</tbody>
</table>
shows various types of traumatic brain injuries (extradural hematoma, contusion, diffuse axonal injury, acute subdural hematoma, subarachnoid hemorrhage). Figure 2 represents a CT scan of right sided acute subdural hematoma with significant midline shift. Figure 3 shows a CT scan of diffuse axonal injury.

**DISCUSSION**

This study gives data on the efficacy of magnesium sulfate and its use in the patients with brain injury. More studies should be conducted to see the effects, efficacy, safety and increase in magnesium levels in the CSF with this therapy. Most studies have been done on the animals so insufficient data is available on human trials which means there is a need for more human clinical trials with magnesium therapy. One study (randomized controlled trial) gives the data regarding the effects of five-day intravenous infusion of magnesium sulfate therapy on the Glasgow coma scale and Glasgow outcome score and showed the comparison between the placebo and magnesium sulfate treatment groups in patients with brain trauma.

In a study done by Ling Zhao et al, (2016) there was significant improvement in GOS in MST (magnesium sulfate therapy) group as compared to placebo group. The mean GOS score was significantly higher in the MST group at discharge and 1 month after discharge consistent with the results of the current study.8

In spite of many clinical trials done on rodent animals which showed the efficacy of magnesium sulfate therapy and improvement in clinical outcome in patients with traumatic brain injury; in a recent study magnesium sulphate therapy didn’t show any efficacy in improvement of clinical outcome.15
Magnesium plasma levels were corrected in all patients, those in magnesium treatment group received additional doses of magnesium at least double magnesium plasma levels as compared to placebo. McKee et al, (2005) mentioned that magnesium didn’t show any improvement in the clinical outcome at double plasma levels rather had serious side effects in many patients as compared to placebo group. The dose response of magnesium as seen in the preclinical studies, brought into attention that in patients with TBI, intravenous magnesium can only slightly increase the CSF magnesium levels.16–17

It’s critical to know that this slight increase in CSF magnesium levels will be sufficient to increase the cellular free magnesium concentration which is mandatory for its neuroprotective properties.17

Habgood et al, (2007) reported that magnesium sulfate levels in the CNS depend on the integrity of blood brain barrier. In studies done on rats, brain injury led to more disruption of blood brain barrier which resulted in excessive magnesium entry into the cells for 24 hours, this doesn’t happen in human CNS after trauma.18–19,20

It is therefore expected that magnesium levels in the cells may not be as in the clinical trials, in this case the peripheral effects of magnesium may be more than the central and will affect the vitals of the patient including the blood pressure and cerebral blood flow.

It is necessary to have more clear knowledge about the entry of magnesium into the human central nervous system to have better results from the therapy.

Neuronal cell death after brain injury has multiple factors that are why combination therapy is recommended in many reports. Combination therapies target more than one factor, have gained attention over the period of time and have more efficacy. Different combination therapies have been studied until now in patients with brain trauma and ischemia like magnesium in combination with growth factors, glutamate antagonists, vitamin B, immunosuppressant, hypothermia, antioxidants. Studies have shown various results in preclinical trials, among them a combination of magnesium and hypothermia had better results. Further clinical studies are recommended to see the efficacy of combined magnesium and hypothermia therapy in patients with brain ischemia.21–22,23

According to the meta-analysis, mortality was almost same between the groups. In a study done by Li et al, (2015)24 the Glasgow outcome score was higher in the magnesium sulphate treatment group as compared to the placebo group, but the significance was marginal; post treatment change in the Glasgow outcome score was significantly higher in the magnesium sulphate treatment group as compared to placebo.24 Magnesium treatment group showed significant improvement in GCS after two months post trauma (p = 0.03). Motor functioning scores of patients in the MgSO4 group were higher than those in the control group but this was not statistically significant (p = 0.51). The study shows that magnesium sulphate treatment has neuroprotective effects in the CNS in patients with severe diffuse axonal injury.25 The results of these studies were in consistent with the results of the current study.

In a study done by Lyons et al, (2018) there was no major improvement in the GOS in the treatment group as compared to the placebo, although, GCS showed a significant improvement in the treatment group which was contrary to this study.26 Maselet al, (2010) is suggested that the magnesium sulphate shows the tendency to significantly improve the Glasgow Outcome Scale and Glasgow Coma Scale score, this is very positive result for traumatic brain injury therapy.27

From the current research it’s quite obvious that the use of magnesium sulphate therapy is beneficial for the patients with traumatic brain injury, it improves the Glasgow Outcome Scale and the Glasgow coma score which is consistent with other studies. More studies need to be done to come to a conclusion that in which type of brain trauma, the magnesium sulphate therapy would have the better outcome.

CONCLUSION

It was observed that the use of the Magnesium sulphate in the patients presenting with the traumatic brain injury must be emphasized and should be used as an add-on therapy along with the standard treatment protocols so that patients could be recovered from the injury. It is further recommended that more studies should be carried out on the trauma patients. Generalizability of the results of this study depends on the future studies.

REFERENCES


20. Miller JW, D. Ambroso R. When basic research does not translate to the bedside lessons from the Magnesium Brain Trauma study. Epilepsy Curr. 2007; 7: 133-5.
Comparison of Mean Glasgow Outcome Score in Patients with Traumatic Brain Injury after Magnesium Sulphate

Additional Information
Disclosures: Authors report no conflict of interest.
Ethical Review Board Approval: The study was conformed to the ethical review board requirements.
Human subjects: Consent was obtained by all patients/participants in this study.
Conflicts of Interest:
In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Financial Relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other Relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Address for correspondence:
Kazim Ali
Punjab Institute of Neurosciences, Lahore
Email: doctorkazimali@hotmail.com

AUTHORSHIP AND CONTRIBUTION DECLARATION

<table>
<thead>
<tr>
<th>Sr.#</th>
<th>Author’s Full Name and Affiliation</th>
<th>Intellectual Contribution to Paper in Terms of:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Muhammad Afaq Sarwar</td>
<td>Study design and methodology.</td>
</tr>
<tr>
<td>2.</td>
<td>Kazim Ali</td>
<td>Paper writing, referencing, data calculations, Data collection, analysis and interpretation</td>
</tr>
<tr>
<td>3.</td>
<td>Muhammad Irfan</td>
<td>Analysis of data and interpretation of results etc.</td>
</tr>
<tr>
<td>4.</td>
<td>Rabia Abbas</td>
<td>Literature review, manuscript writing and referencing</td>
</tr>
<tr>
<td>5.</td>
<td>Kamran Hussain</td>
<td>Analysis of data and quality insurer</td>
</tr>
</tbody>
</table>

Date of Submission: 18-4-2020
Date of Revision: 01-06-2020
Date of Online Publishing: 30-06-2020
Date of Print: 30-07-2020